Aer Therapeutics

Aer Therapeutics is a clinical-stage biopharmaceutical company based in the Research Triangle Park / Raleigh area of North Carolina, developing novel treatments for muco-obstructive lung diseases such as COPD, asthma, cystic fibrosis, and non-CF bronchiectasis. A spinout from Dr. John Fahy's laboratory at the University of California, San Francisco (UCSF), the company's lead candidate, AER-01 (fexlamose), is an inhaled small-molecule mucolytic designed to break down and liquefy the dense mucus plugs that obstruct airflow in the lungs. Aer closed a $36 million Series A backed by life-science investors including Canaan, OrbiMed, Hatteras Venture Partners, and Pappas Capital. Aer Therapeutics is a private, research-focused therapeutics company and does not publish a public developer platform, API, or SDKs; this profile captures its corporate identity within the API Evangelist network.

Aer Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Biotechnology, Therapeutics, and Life Sciences.

Aer Therapeutics’ developer surface includes support and 5 more developer resources.

🌐 Visit website 📡 Source on GitHub

14.6/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyBiopharmaceuticalBiotechnologyTherapeuticsLife SciencesRespiratoryPharmaceuticalsClinical Stage

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 14.6/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.9 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.0 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/aer-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 2

The organization behind the API

Website

Website

LinkedIn

Source (apis.yml)

aid: aer-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/aer-therapeutics.png
name: Aer Therapeutics
description: Aer Therapeutics is a clinical-stage biopharmaceutical company based in the Research Triangle Park / Raleigh
  area of North Carolina, developing novel treatments for muco-obstructive lung diseases such as COPD, asthma, cystic fibrosis,
  and non-CF bronchiectasis. A spinout from Dr. John Fahy's laboratory at the University of California, San Francisco (UCSF),
  the company's lead candidate, AER-01 (fexlamose), is an inhaled small-molecule mucolytic designed to break down and liquefy
  the dense mucus plugs that obstruct airflow in the lungs. Aer closed a $36 million Series A backed by life-science investors
  including Canaan, OrbiMed, Hatteras Venture Partners, and Pappas Capital. Aer Therapeutics is a private, research-focused
  therapeutics company and does not publish a public developer platform, API, or SDKs; this profile captures its corporate
  identity within the API Evangelist network.
url: https://raw.githubusercontent.com/api-evangelist/aer-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- canaan-partners
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Biopharmaceutical
- Biotechnology
- Therapeutics
- Life Sciences
- Respiratory
- Pharmaceuticals
- Clinical Stage
apis: []
common:
- type: DomainSecurity
  url: security/aer-therapeutics-domain-security.yml
- type: Website
  url: https://aertherapeutics.com
- type: TermsOfService
  url: https://aertherapeutics.com/terms-of-service/
- type: PrivacyPolicy
  url: https://aertherapeutics.com/privacy-policy/
- type: Support
  url: https://aertherapeutics.com/contact-us/
- type: LinkedIn
  url: https://www.linkedin.com/company/aer-therapeutics-inc.
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence